Dataset Information


A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer.

ABSTRACT: A diversity of T helper (Th) subsets (Th1, Th2, Th17) has been identified in the human tumor microenvironment. In breast cancer, the role of Th subsets remains controversial, and a systematic study integrating Th subset diversity, T cell inflammation, breast cancer molecular subtypes, and patient prognosis, is lacking. In primary untreated breast cancer samples, we analyzed 19 Th cytokines at the protein level. Eight were T cell-specific, and subsequently measured in 106 prospectively-collected untreated samples. The dominant Th cytokines across all breast cancer samples were IFN-? and IL-2. Th2 cytokines (IL-4, IL-5, IL-13) were expressed at low levels and not associated with any breast cancer subtype. Th17 cytokines (IL-17A and IL-17F) were up-regulated in triple negative breast cancer (TNBC), specifically in T cell non-inflamed tumors. In order to get insight into prognosis, we exploited the METABRIC transcriptomic dataset. We derived Th1, Th2, and Th17 metagenes based on manually curated Th signatures, and found that a high Th17 metagene was of good prognosis in T cell non-inflamed TNBC. Multivariate Cox modeling selected the Nottingham Prognostic Index (NPI), Th2 and Th17 metagenes as additive predictors of breast cancer-specific survival, which defined novel and highly distinct prognostic groups within TNBC. Our results reveal that Th17 is a novel prognostic composite biomarker in T cell non-inflamed TNBC. Integrating immune cell and tumor molecular diversity is an efficient strategy for prognostic stratification of cancer patients.

SUBMITTER: Faucheux L 

PROVIDER: S-EPMC6685521 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3912696 | BioStudies
2013-01-01 | S-EPMC3954848 | BioStudies
2011-01-01 | S-EPMC3262210 | BioStudies
2020-01-01 | S-EPMC7004338 | BioStudies
2019-01-01 | S-EPMC6747459 | BioStudies
2015-01-01 | S-EPMC4403992 | BioStudies
2012-01-01 | S-EPMC3441148 | BioStudies
2020-01-01 | S-EPMC7566124 | BioStudies
2014-01-01 | S-EPMC4007196 | BioStudies
2009-01-01 | S-EPMC2630122 | BioStudies